Compare Ascendis Pharma A/S (ASND) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs VF Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while VF Corp trades at $16.56 (market cap $6.58B). The key difference: Ascendis Pharma A/S is far larger — about 2.7× VF Corp's market cap, and VF Corp pays a 2.15% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VFC | |
|---|---|---|
Market Cap | $17.74B | $6.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $21.55 |
52-Week Low | $163.32 | $11.66 |
Enterprise Value | $18.11B | $10.73B |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VFC trades at $16.77, up 1.45% on the day, amid a mixed technical and fundamental backdrop. The stock is bearish on moving averages but shows neutral oscillators, with key support at $16. Recent earnings have been volatile, with a Q1 2026 miss after previous beats, while revenue has declined from $11.8B in 2022 to $9.5B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M for 2025. Analyst sentiment is mixed with a consensus price target of $20.00.
The outlook for VFC hinges on a successful turnaround, with projected net income turning positive in 2026. Near-term risks include weak consumer confidence and brand-specific challenges at Vans. The current valuation, with a P/S of 0.69, may appeal to value investors if operational improvements continue, but execution risks and high debt levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
